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Severe acute pancreatitis (SAP) can cause intestinal barrier dysfunction (IBD), which signiﬁcantly increases the disease severity
and risk of mortality. We hypothesized that the innate immunity- and inﬂammatory-related protein-triggering receptor expressed
on myeloid cells-1 (TREM-1) contributes to this complication of SAP. Thus, we investigated the eﬀect of TREM-1 pathway
modulation on a rat model of pancreatitis-associated IBD. In this study we sought to clarify the role of TREM-1 in the
pathophysiologyofintestinalbarrierdysfunctioninSAP.Speciﬁcally,weevaluatedlevelsofserumTREM-1andmembrane-bound
TREM-1 in the intestine and pancreas from an animal model of experimentally induced SAP. TREM-1 pathway blockade by LP17
treatment may suppress pancreatitis-associated IBD and ameliorate the damage to the intestinal mucosa barrier.
1.Introduction
Severe acute pancreatitis (SAP) can readily progress from a
localized inﬂammation of the pancreas to a systemic disease
and may lead to multiple organ dysfunction syndrome
(MODS). The intestinal mucosal barrier plays a pivotal
role in the pathophysiology of SAP, as the intestine is a
primary target organ of inﬂammation-induced dysfunction
and an initiator of MODS. A large number of studies have
demonstrated that SAP is strongly associated with develop-
ment of intestinal barrier dysfunction (IBD) [1, 2]. On the
other hand, IBD caused by bacterial translocation, intestinal
infection, or endotoxin exposure can aggravate SAP, and
this complicating event has been proposed as a major cause
of SAP death [3]. Unfortunately, the underlying molecular
mechanisms that mediate the relationship between injury of
the intestinal mucosa barrier and SAP remain to be fully
elucidated.
The triggering receptor expressed on myeloid cells-1
(TREM-1) protein was recently described as a diagnostic
marker of inﬂammation, as it is induced in the presence of
bacteria or endotoxin. TREM-1 is mainly expressed on neu-
trophils and monocytes/macrophages where it functions in
synergy with Toll-like receptor-mediated signals to increase
the release of proinﬂammatory factors, such as TNF-α and
IL-lβ [4, 5]. Hence, TREM-1 acts as a critical ampliﬁer of
inﬂammatory signaling in response to lipopolysaccharide
(LPS) and other microbial products [6].
Patients with acute pancreatitis (AP) are characterized by
a high expression level of TREM-1 mRNA in leukocytes [7].
Moreover, intestinal expression of TREM-1 is upregulated
in IBDs and correlates with disease severity [8]. Recent
investigations have demonstrated that membrane-bound
TREM-1 protein is increased in the pancreas, liver, and kid-
ney of patients with SAP, suggesting that TREM-1 may act
as an important mediator of inﬂammation and subsequent
extrapancreatic organ injury in SAP [9].
In this study we sought to clarify the role of TREM-
1 in the pathophysiology of IBD in SAP. Speciﬁcally, we
evaluated levels of serum TREM-1 and membrane-bound
TREM-1 in the intestine and pancreas from an animal2 Gastroenterology Research and Practice
model of experimentally induced SAP. Based on the TREM-
1 sequence in the GenBank/EMBL/DDBJ (under accession
nos. AF287008 and AF241219); a highly conserved domain
(LQVTDSGLYRCVIYHPP) in rats, mice, and humans in
the extracellular region of the protein was chemically syn-
thesized as a COOH terminally amidated peptide (Pepscan
Systems) and was designated as LP17 [10, 11]. LP17 can
compete with the natural ligand of TREM-1 for binding
and is believed to act as a so-called decoy receptor. The
correct peptide was obtained in >99% yield and was
homogeneous after preparative puriﬁcation, as conﬁrmed
by mass spectrometry and analytic reversed-phase high-
performance liquid chromatography. A scrambled peptide
containingthesameaminoacidsasLP17,butinacompletely
diﬀerent sequence order (TDSRCVIGLYHPPLQVY), was
similarly synthesized and designated as TY17 to serve as a
negative control. Both in vitro and in vivo treatment with
LP17, a synthetic peptide blocker of the TREM-1 pathway,
eﬃciently suppressed and prevented the detrimental eﬀects
of proinﬂammatory cytokines. Our ﬁndings indicated that
blockade of the TREM-1 pathway by LP17 mitigates the
inﬂammatory response associated with SAP and provides
therapeutic protection from intestinal mucosal damage.
2.MaterialsandMethods
2.1. Materials
2.1.1. Animals. Male Wistar rats (weighing 250–300g, 9
weeks old) were purchased from the Laboratory Animal
Center of Jiangsu University. The rats were allowed to
acclimatize to the laboratory conditions for 7d under a
12h light-dark cycle at a constant temperature of 21 ± 1◦C.
The animals were fasted for 12h before experiments but
allowed free access to water. All experimental procedures
were performed in accordance with the Guide for the Care
and Use of Laboratory Animals and approved by the Animal
Ethics Committee of Jiangsu University, China.
2.2. Induction of Experimental SAP. After 12h of fasting,
animals were anesthetized by intraperitoneal injection of
50mg/kg phenobarbital, and a midline laparotomy was
performed. SAP was induced by retrograde injection of 5%
sodium taurocholate (TCA; 1mL/kg body weight) into the
biliopancreatic duct in a pressure- and volume-controlled
manner over 10min. Sham-operated rats were used as non-
SAP (healthy) controls, in which only the laparotomy was
performed.
2.3. Experimental Grouping. A total of 64 healthy male
Wistar rats were randomly divided into sham-operated
group, SAP group, SAP + LP17, and SAP + TY17 group with
16ratsineachgroup.Eightratsineachgroupwereonlyused
for intestinal permeability assessment. Based on the results
of previous studies, the rat intestinal injury has been found
serious at 6h after TCA injection; therefore, rats were used
6h after injection to investigate SAP associated with IBD
[12]. LP17 or TY17 was administered intravenously (1.0mg
in 0.1mL of saline) just before the induction of pancreatitis.
2.4. Rat Blood Samples. Six hours after the rat SAP model
was established, the rats were re-anesthetized, and blood
samples were drawn from the heart. The blood samples
were individually collected into dry, sterile test tubes and
centrifuged at 2500×g for 15min; serum was removed and
stored at −80◦C until use.
2.5. Analysis of Serum TREM-1, Serum Diamine Oxidase
(DAO), and D-Lactate. The amount of TREM-1 in rat blood
serum was determined in duplicate using ELISA kits (GBD,
Canada) as described by the manufacturer’s protocol. The
serums were quantitated for DAO and D-lactate concentra-
tionsusingcommercialkitsandfollowingthemanufacturer’s
protocol (Genmed, China) by spectrophotometric measure-
ments.
2.6.AnalysisofTREM-1,TNF-α,andIL-1βmRNAinIntestine
and Pancreas by Real-Time Quantitative (qRT-)PCR. Distal
ileums and pancreatic tissue samples were collected and
stored at −80◦C when the animals were sacriﬁced. Total
RNA was isolated from rat intestinal mucosa and pancreas
using TRIzol reagent (Invitrogen Corp., USA), according
to the manufacturer’s instructions. Complementary DNA
(cDNA) was synthesized using a reverse-transcription kit
(Toyoba, Japan). The cDNAs were subjected to qRT-PCR
using the SYBR Premix Ex Taq (Takara, Japan) on a Rotor-
Gene 6000 instrument. Primers were designed as follows: rat
TREM-1, forward 5 -AAGTATGCCAGAAGCAGGAAGG-
3  and reverse 5 -GGTAGGGTCATCTTTCAGGGTGT-3 ;
rat TNF-α,f o r w a r d5  -CGTCGTAGCAAACCACCAAG-3 
and reverse 5 -CACAGAGCAATGACTCCAAAG-3 ;r a tI L -
1β,f o r w a r d5  -AATACCACTTGTTGGCTTA-3  and reverse
5 -TGTGATGTTCCCATTAGAC-3 ;r a tβ-actin, forward
5 -CCTGTACGCCAACACAGTGC-3  and reverse 5 -ATA-
CTCCTGCTTGCTGATCC-3 . The comparative Ct method
(2−ΔΔCt) was used to calculate the relative gene expression
levels [13].
2.7. Intestinal Permeability Assessment. Intestinal permeabil-
ity was quantiﬁed using the lactulose/mannitol (L/M) test
as previously described by Hang et al. [14] with high-
pressure liquid chromatograph (HPLC). Eight hours before
the animals were sacriﬁced at 6h after TCA injection in
each group, the rats with their bladders emptied were given
the test solution of 2mL by gastric tube feeding, containing
100mglactuloseand60mgmannitol.Allurinewascollected
for 8 hours through the metabolic cage and stored at −20◦C
for further analysis. Results were expressed as a ratio of the
two molecules excreted.
2.8. Testing for Bacterial Translocation. Mesenteric lymph
nodes in 8 rats in each group were taken for bacteriologic
cultures. Collected tissue samples were weighed, and 0.5g
of each was homogenized in a tissue grinder with 4.5mL
sterile saline solutions (SS) to made 10% tissue-slurry,Gastroenterology Research and Practice 3
then 0.1mL solutions immediately cultured in agar-blood
medium plates. Inoculated plates were incubated at 37◦Cf o r
24 hours. Cultures were considered positive when more than
100 colonies per gram of tissue were found.
2.9. Pathological Examination. Upon excision, the pancreas
and distal ilea (5cm long) were promptly ﬁxed in 4%
formalin and embedded in paraﬃn wax, following standard
procedures. Paraﬃn-embedded pancreas and distal ilea were
sectioned (5μm), then stained with hematoxylin and eosin
(H&E).Thedegreeofmucosaldamagewasgradedaccording
to the standard scale of Chiu et al. [15]: 0 = normal mucosa,
1 =developmentofsubepithelialspaceatthetipofthevillus,
2 = extension of the space with epithelial lifting, 3 = massive
epithelial lifting, 4 = denuded villi, and 5 = disintegration of
the lamina propria.
2.10. Statistical Analysis. All the data were expressed as
mean ± standard deviations (SDs) using SPSS statistical
software (version 18.0) and GraphPad Prism 5.0. If equal
variances were assumed, one-way ANOVA was used. The
d e g r e eo fm u c o s a ld a m a g ei ne a c hg r o u pw a se v a l u a t e d
using the Mann-Whitney U test. P<0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Levels of TREM-1 in Serum. Levels of soluble TREM-
1 in serum in the SAP group and SAP + LP17 group were
signiﬁcantly higher than those in the sham group and SAP +
LP17 group (P<0.05, Figure 1).
3.2. The Expression of TREM-1, TNF-α,a n dI L - 1 β mRNA.
Our results indicated that the TREM-1, TNF-α,a n dI L -
1β mRNA expressed in the SAP group and SAP + LP17
group were signiﬁcantly higher than those in the sham group
and SAP + LP17 group in intestinal tissues (P<0.05).
Pretreatment with LP17 signiﬁcantly decreased the expres-
sion of TREM-1, TNF-α,a n dI L - 1 β levels in the SAP group.
The TREM-1 expressed in pancreatic tissues in the SAP
group and SAP + LP17 group was signiﬁcantly higher than
that in the sham group and SAP + LP17 group. These data
suggested that LP17 may attenuate intestinal mucosa injury
inducedbytheinﬂammatoryresponsemediatedbythesetwo
cytokines (Figures 2 and 3).
3.3. Levels of DAO and D-Lactate in Serum. Spectrophotom-
etryresultsrevealedthatthelevelsofDAOandD-lactatewere
distinctly higher in the SAP group and SAP + LP17 group
than those in the sham group. However, the levels of DAO
and D-lactate in the SAP + LP17 group were lower than
either the SAP group or the SAP + TY17 group (P<0.05,
Figure 4).
3.4. Intestinal Permeability (Lactulose and Mannitol Assay).
As shown in Figure 5, intestinal permeabilities in the SAP
group and the SAP + LP17 group were signiﬁcantly higher
















































Figure 1: Levels of TREM-1 in serum in each group.
∗P versus
sham group, #P versus SAP group, ΔP versus SAP + LP17 group
(P<0.05, as below).
administration to SAP caused a clear deterioration in the
mucosal permeability, as assessed by the L/M ratio than that
in the SAP group and the SAP + TY17 group (P<0.05).
3.5. Quantitative Bacteriologic Culture of MLNs. Tissue cul-
tures tested positive for bacteria in all animals in the SAP
group and SAP + LP17 group. In contrast, only one of seven
animals in the sham group showed positive tissue cultures.
The percentages of positive harvested MLNs in the SAP +
LP17 group were lower than either the SAP group or the
SAP + TY17 group. Data are presented as percentages of
harvested tissue samples (P<0.05, Figure 6).
3.6. PathologicExaminationofPancreasandIntestinalMucosa
Gross Observation. In the sham group, the pancreas showed
no signiﬁcant changes. In the SAP group or the SAP +
TY17 group, bloody ascites in the abdominal cavity as well
as pancreatic congestion, edema, hemorrhage, and necrosis,
was noted. In the SAP + LP17 group; pathological changes
were milder than those in the SAP group or the SAP + TY17
group.
Light Microscopy. In the sham group, the pancreas of
rats showed no morphological or structural abnormalities
Figure 7(a); in SAP group or the SAP + TY17 group there
were varying degrees of focal interlobular edema, necrotic
areas without structure, and red blood cells in the tissue
space, as well as massive inﬂammatory cell inﬁltration
Figures 7(b) and 7(d);i nt h eS A P+L P 1 7g r o u pFigure 7(c),
pancreatic edema, hemorrhage, and necrosis, as well as
inﬂammatory cell inﬁltration, were milder than in SAP
group or the SAP + TY17 group (Figure 7).
After induction of SAP, the rats exhibited characteristic
pathological changes such as broadened villi, inﬁltration
of inﬂammatory cells, and parenchyma hemorrhage in the
SAP group or the SAP + TY17 group. Treatment with












































































































Figure 2: The expression of TREM-1 in the intestinal and pancre-
atic tissues.
and decreased red blood cells in the interstitial space were
observed (Figure 8). The degree of intestinal pathological
injury is shown in (Figure 9).
4. Discussion
The results of our study show that increases in serum and
membrane-boundTREM-1levelsaresigniﬁcantlyassociated
with SAP disease severity and IBD in rats. Moreover, we also
found that blockade of the TREM-1 pathway, by means of
LP17 treatment, can ameliorate intestinal mucosal damage
and systemic inﬂammation, and this ﬁnding suggests that
TREM-1 may be a potential therapeutic target for SAP-
associated IBD.
The intestine represents the largest immune organ of the
h u m a nb o d y .T h ei m m u n ef u n c t i o ni sa ni m p o r t a n tp a r t
of the intestinal epithelial barrier, which actively prevents
and resolves pathogenic infection. Intestinal mucosa injury
in case of SAP is one of the main reasons for the accelerated
aggravation of this disease. Unfortunately, the underlying









































































































Figure 3: The expression of IL-1β (a) and TNF-α (b) mRNA in the
intestinal tissues.
understood, and an eﬀective means to prevent SAP compli-
cations related to IBD has yet to developed.
It was initially reported that TREM-1 acted as an am-
pliﬁer of inﬂammation by enhancing degranulation and
secretion of proinﬂammatory mediators. Increased levels of
soluble TREM-1 (sTREM-1) have been detected in patients
and animals suﬀering from a variety of infectious and
noninfectiousdiseases,oftencorrelatingwithdiseaseseverity
[16–18]. In patients suﬀering from AP, serum sTREM-1 was
found to be higher than that in healthy individuals [19].
In our study using the rat model of induced SAP, both
serumsolubleTREM-1levelsandmembrane-boundTREM-
1 expression in intestine tissue were signiﬁcantly increased at
6h after the induction of pancreatitis, and those increased
levels persisted over time. Yasuda et al. reported that the
early phase and the late phase (18h after the induction)
of AP were associated with blood endotoxin and bacterial
translocation events [20]. Another recent study found that
Gram-negative bacteria-derived bacterial DNA was present
at detectable levels in AP patients’ serum [21]. Therefore,
we theorized that serum sTREM-1 levels and membrane-
bound TREM-1 expression in the very early phase of SAP














































































































Figure 4: Levels of DAO and D-lactate in serum.
response (or the systemic inﬂammatory response) [22, 23].
Subsequently, in the late phase of SAP, sTREM-1 in serum
may be increased in response to undetectable microbes
or endotoxin. The results of this study showed that the
expression levels of TREM-1 protein and the pathological
severity scores of the intestinal mucosa of SAP rats in
SAP group were signiﬁcantly higher than those in the
sham group, indicating that the mucosa damage may be
related to upregulation of TREM-1 protein. Pancreatitis-as-
s o c i a t e dI B Dp r o g r e s s e sa sb l o o dm o n o c y t e sa r er e c r u i t e d
and produce proinﬂammatory cytokines; hence, we think
membrane-bound TREM-1 upregulation in the intestine
and pancreas is increased on the inﬁltrating neutrophils in
response to the inﬂammation cascade in process, and these
systemic responses may be closely related to organ damage
(and MODS).
To therapeutically block the TREM-1 pathway, we ad-
ministered the peptide (LP17) by intravenous injection. This
peptide had been originally designed by Gibot et al. and was
derived from the extracellular domain of TREM-1. The LP17
has been demonstrated by others to be of therapeutic beneﬁt
duringsepsisandacutemesentericischemia-reperfusion[24,

























Figure 5: Intestinal permeability, as assessed by the lactu-










































Figure 6: Quantitative bacteriologic culture of MLNs.
TREM-1 expression was associated with the common IBDs,
ulcerative colitis (UC), and Crohn’s disease (CD). In exper-
imental mouse models of UC and in human patients with
CD, TREM-1 expression in the intestine was upregulated
and correlated with disease severity. Furthermore, blocking
TREM-1 by means of treatment with LP17 was shown to
decrease disease severity. In our study, we constructed the
SAP animal model by treatment with TCA and detected the
two characteristic markers of intestinal barrier dysfunction
caused by SAP, D-lactate, and DAO. We found that LP17
can reduce the levels of D-lactate and DAO in TCA-
induced SAP rats. This ﬁnding indicated that treatment with
LP17 signiﬁcantly improved intestinal barrier function and
reduced the extent of intestinal mucosal damage associated
with SAP.
The action of proinﬂammatory cytokines is another
important injury-inducing mechanism that impacts the
integrity of the intestinal mucosa. Excessive release of
inﬂammatory mediators, such as IL-1β and TNF-α,c a n
directly damage the intestinal mucosa barrier [26]. TNF-α,
in particular, participates in the early steps of SAP and can
induce expression of other inﬂammatory cytokines [27–29].6 Gastroenterology Research and Practice
(a) (b)
(c) (d)
Figure 7: Pathological changes in the pancreas. (a) Sham, (b) SAP, (c) SAP + LP17, (d) SAP + TY17.
(a) (b)
(c) (d)














































Figure 9: Histological score of the ileum at 6h after the induction
of SAP.
In addition, TNF-α is known to stimulate the generation of
several injuring substances, such as nitric oxide (NO) and
oxygen-free radicals, which can lead to further inﬂammatory
cascade and ampliﬁcation eﬀects [30, 31]. TNF-α can also
promote the permeability of intestinal mucosa barriers and
break down the tight junctions so that intestinal bacteria
may easily transverse into the mesenteric lymph nodes
and other organs [32]. Continuous invasion of intestinal
bacteria and endotoxin into the body will lead to the
life-threatening systemic inﬂammatory response syndrome
(known as SIRS) and MODS. IL-1β is another classic
proinﬂammatory cytokine; it can destroy the endothelial
barrier integrity by stimulating the release of inﬂammatory
mediators from leukocytes and endothelial cells. On the
other hand, compromised endothelial cells can enhance the
synthesis and secretion of IL-1β [33]. Some results found
that resident intestinal macrophages have an inherent ability
to produce TNF-α. Activation of intestinal macrophages by
unknown substances may contribute to the induction of
TNF-αproduction,whichcausestheintestinalinﬂammation
[34]. So we use LP17 to block the TREM-1 pathway of
local intestinal macrophages and inﬁltrating neutrophils in
intestine and observe the changes of TNF-α and IL-1β
production.
TostudytheeﬀectofLP17onbothoftheseproinﬂamma-
tory cytokines, we used qRT-PCR to determine the mRNA
level of IL-1β and TNF-α in intestinal mucosa. Our results
showed that the expressions of IL-1β mRNA and TNF-
α mRNA were signiﬁcantly suppressed by LP17 treatment
in our rat SAP models, suggesting that LP17 may exert
protective eﬀects on the small intestine by mitigating the
inﬂammatory response. This result is in agreement with
other related recent investigations. So we believe that LP17
can inhibit the expression of TREM-1 in both local intestinal
macrophages and inﬁltrating neutrophils from blood.
Inconclusion,ourdatasuggestthatTREM-1participates
in pancreatitis-associated IBD, and pretreatment with LP17
is able to reduce the severity of intestinal injury. LP17 acts
to diminish the release of IL-1β and TNF-α in the intestine
during the early phase of SAP. The modulation of TREM-
1 signaling by the use of a synthetic peptide such as LP17
appears to be a promising therapeutic approach for the
treatment of acute pancreatitis complicated by injury of the
intestinal mucosa barrier.
Although LP17 treatment in our rat model was eﬃca-
cious, some considerations should be noted. To obtain a suc-
cessful model of SAP, we chose not to administer antibiotics
to the rats, but in clinic most of the patients who have SAP
receive early and adequate antibiotic therapy. The TREM-
1 ligands are not known at present; future studies directed
at identiﬁcation of natural ligands of TREM-1 will advance
our understanding of its physiological signiﬁcance during
an immune response against microbial and nonmicrobial
inﬂammation.
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